Research programme: T-cell activated therapeutics - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Drug Profile

Research programme: T-cell activated therapeutics - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Alternative Names: Allogeneic T-cell therapies - Atara/MSKCC

Latest Information Update: 15 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Atara Biotherapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer
  • Research Autoimmune disorders

Most Recent Events

  • 08 May 2018 Atara Biotherapeutics expands T-Cell immunotherapy collaboration to advance next-generation CAR T technologies in oncology, autoimmune and other diseases
  • 08 May 2018 Early research in Autoimmune disorders in USA (Parenteral)
  • 16 Oct 2017 Atara Biotherapeutics plans a phase I trial of allogenic ATA 188 for Multiple sclerosis in USA in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top